Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

INCYTE CORPORATION

(INCY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Incyte : Signs Supply, Distribution Deal for Tafasitamab, Pemigatinib in Latin America

09/23/2021 | 08:03am EST


ę MT Newswires 2021
All news about INCYTE CORPORATION
11/19BMO Capital Starts Incyte at Market Perform With $75 Price Target
MT
11/18Novartis Said Considering Takeover in Biotech Sector
MT
11/09Incyte to Present at Upcoming Investor Conference
BU
11/08First Patient Dosed in SELECT-AML-1 Trial of Tamibarotene and in Dose Confirmation Stud..
AQ
11/04JMP Securities Adjusts Price Target on Incyte to $108 from $124, Keeps Market Outperfor..
MT
11/04More than 35 Abstracts from Incyte's Oncology Portfolio Accepted for Presentation at th..
BU
11/04SEC Brings Insider Trading Out Of The Shadows
AQ
11/03Oppenheimer Adjusts Price Target on Incyte to $109 from $110; Keeps Outperform Rating
MT
11/02INCYTE CORP Management's Discussion and Analysis of Financial Condition and Results of..
AQ
11/02Corporate Statement Regarding Opzelura™ (ruxolitinib) Cream - Form 8-K
PU
More news
Analyst Recommendations on INCYTE CORPORATION
More recommendations
Financials (USD)
Sales 2021 2 928 M - -
Net income 2021 525 M - -
Net cash 2021 2 043 M - -
P/E ratio 2021 29,2x
Yield 2021 -
Capitalization 15 105 M 15 105 M -
EV / Sales 2021 4,46x
EV / Sales 2022 3,54x
Nbr of Employees 1 773
Free-Float 98,5%
Chart INCYTE CORPORATION
Duration : Period :
Incyte Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INCYTE CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 68,38 $
Average target price 94,47 $
Spread / Average Target 38,2%
EPS Revisions
Managers and Directors
Herve Hoppenot Chairman, President & Chief Executive Officer
Christiana Stamoulis Chief Financial Officer & Executive Vice President
Steven H. Stein Chief Medical Officer & Executive Vice President
Dashyant Dhanak Chief Scientific Officer & Executive VP
Julian Charles Baker Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
INCYTE CORPORATION-21.38%15 105
MODERNA, INC.215.53%133 648
LONZA GROUP AG29.85%59 443
IQVIA HOLDINGS INC.46.26%50 064
SEAGEN INC.-3.22%30 994
CELLTRION, INC.-40.39%24 431